eFFECTOR Therapeutics

eFFECTOR Therapeutics ROE

The Return on Equity (ROE) of eFFECTOR Therapeutics (EFTR) as of Oct 20, 2026 is 617.96 %. In the previous year, Return on Equity (ROE) was -581.75 % — a change of -206.22% (higher).

ROE

617.96 %

YoY

-206.22%

Last updated:

In 2023, eFFECTOR Therapeutics's return on equity (ROE) was 617.96 %, a -206.22% increase from the -581.75 % ROE in the previous year.

The eFFECTOR Therapeutics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
102.68 USD
Jan 1, 2020
16.96 USD
Jan 1, 2021
91.40 USD
Jan 1, 2022
-581.75 USD
Jan 1, 2023
617.96 USD
The eFFECTOR Therapeutics ROE history
YEARROEYoY
617.96 %-206.22%
-581.75 %-736.47%
91.40 %+439.05%
16.96 %-83.49%
102.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

eFFECTOR Therapeutics Stock analysis

What does eFFECTOR Therapeutics do? eFFECTOR Therapeutics Inc, based in Solana Beach, US, is a clinical-stage biopharmaceutical company specializing in oncology drug development. The company focuses on selective translation regulator inhibitors (STRIs), targeting the eIF4F complex and MNK kinase. Its lead candidate tomivosertib, in a Phase 2b trial with KEYTRUDA for metastatic NSCLC, and second candidate zotatifin, in Phase 1/2 trials for solid tumors, are part of its pipeline. The company, listed on January 8, 2021, employs 15 people. eFFECTOR Therapeutics is one of the most popular companies on Eulerpool.

ROE Details

Decoding eFFECTOR Therapeutics's Return on Equity (ROE)

eFFECTOR Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing eFFECTOR Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

eFFECTOR Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in eFFECTOR Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about eFFECTOR Therapeutics stock

Return on Equity (ROE) of eFFECTOR Therapeutics is 617.96 % in 2023.

Return on Equity (ROE) of eFFECTOR Therapeutics changed from -581.75 % to 617.96 %, representing a -206.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) eFFECTOR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s eFFECTOR Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — eFFECTOR Therapeutics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — eFFECTOR Therapeutics